Difference between revisions of "SPECT Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
Line 1: Line 1:
 +
{{TOCright}}
 
:Co-chairs: Yuni Dewaraja, PhD; P. David Mozley, MD; John Seibyl, MD  
 
:Co-chairs: Yuni Dewaraja, PhD; P. David Mozley, MD; John Seibyl, MD  
 
:Secretary: Julie Lisiecki
 
:Secretary: Julie Lisiecki
Line 5: Line 6:
 
==Project Snapshot==
 
==Project Snapshot==
 
The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging.   
 
The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging.   
−
 
  
 
'''Under consideration:'''
 
'''Under consideration:'''
Line 11: Line 11:
 
*quantifying organs, like the liver, for dosimetry as potential use cases
 
*quantifying organs, like the liver, for dosimetry as potential use cases
  
−
 
+
'''Established Task Forces currently working toward a first Profile titled:
−
'''Established Task Forces Currently Working Toward a first Profile with title as follows below:
 
 
   
 
   
 
<font color=blue>''Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease''</font>   
 
<font color=blue>''Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease''</font>   
Line 23: Line 22:
 
==Meetings/Call Summaries==
 
==Meetings/Call Summaries==
 
*[[SPECT Call Summaries]]
 
*[[SPECT Call Summaries]]
−
 
−
 
−
==Working Documents==
 
  
 
==Literature Review (Profile 1.0)==
 
==Literature Review (Profile 1.0)==
Line 54: Line 50:
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.02.17.docx | QIBA DRAFT Profile: Quantifying Dopamine Transporters with 123-Iodine Labeled Ioflupane in Neurodegenerative Disease - {comments from Mr. Cella}]] ''February 17, 2016''
 
*[[Media:001.QIBA_SPECT_Profile.v0.1_2016.02.17.docx | QIBA DRAFT Profile: Quantifying Dopamine Transporters with 123-Iodine Labeled Ioflupane in Neurodegenerative Disease - {comments from Mr. Cella}]] ''February 17, 2016''
  
−
==Archived versions of the Profile==
+
*[[Profile drafts|Archived past versions of the Profile]]
−
*[[Profile drafts]]
 
−
 
 
−
==Statistical Reference Documents==
 
−
 
−
 
 
−
==Workflow Documents==
 
  
  
−
 
 
==Reference Materials==
 
==Reference Materials==
  

Revision as of 20:26, 17 March 2017

Co-chairs: Yuni Dewaraja, PhD; P. David Mozley, MD; John Seibyl, MD
Secretary: Julie Lisiecki
Roster: (Roster)

Project Snapshot

The SPECT Biomarker Committee seeks to develop a quantitative imaging profile for SPECT imaging.

Under consideration:

  • quantifying a small structure (like the basal ganglion in the DaTscan, thyroid)
  • quantifying organs, like the liver, for dosimetry as potential use cases

Established Task Forces currently working toward a first Profile titled:

Quantifying Dopamine Transporters with 123-Iodine labeled Ioflupane in Neurodegenerative Disease

  • Image Acquisition and Image Processing for DaTscan – Dr. Dewaraja
  • Quantitative / Image Analysis – Drs. Miyaoka and Seibyl
  • Phantoms / DRO Group – Drs. Dickson and Zimmerman
  • Clinical / Literature Review – Dr. Seibyl

Meetings/Call Summaries

Literature Review (Profile 1.0)

Profile Development


Reference Materials


Retrieved from "https://qibawiki.rsna.org/index.php?title=SPECT_Biomarker_Ctte&oldid=11055"